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Based primarily on studies in the mouse, it has been postulated that at least two
separate lineages ofB cells exist (reviewed in reference 1). The first lineage, charac-
terized by the cell surface expression of the Ly-1 antigen, appears to be primarily
responsible for the secretion ofantibodies that display extensive autoreactivity. The
second lineage, characterized bythe lackofLy-1 expression, is primarily responsible
for the production of "conventional", non-self-reactive antibodies (2-5). This dis-
tinction has been most convincingly demonstrated in inbred strains of mice with
ageneticpredisposition forthedevelopmentofvarious autoimmune syndromes (6, 7).
The humancounterpart ofthe Ly-1 antigen, recently termed CD5, was originally
defined using the anti-Leu-1 mAb (8). In this (8) and subsequent (9-12) studies,
it was demonstrated that the expanded monoclonal population ofB cells that de-
velops in patients with chronic lymphocytic leukemia (CLL)' expresses the CD5
molecule. Thus, CLL appears to represent a clonal overexpansion of the putative
autoantibody-producing B lymphocyte. In support ofthis notion are theclinical ob-
servations that the sera of patients with CLL occasionally contain autoantibodies
and that -20% of such patients develop autoimmune phenomena such as hemo-
lytic anemia (13).
On the basis of these findings, the following prospective studies were performed
to determine, at the clonal level, ifthe C135-expressingB cells in patients with CLL
and other CD5' B lymphoproliferative disorders secrete mAbs reactive with auto-
antigens. These in vitro studies demonstrate that leukemic cells from >50% ofpa-
tients with overexpansions ofCD5' cells synthesize and can be made to secrete Ig
that is autoreactive. Considering that these secreted mAbs were screened for reac-
tivity with only alimited panel ofautoantigens, it is conceivable that aneven higher
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percentage of B CLL clones may be programmed for self reactivity. These studies
provide direct evidence for the secretion of autoantibodies by monoclonal popula-
tions of CD5-expressing cells and also confirm a link between CD5 + leukemias and
autoimmune disease in general.
Materials and Methods
Subjects.
￿
Sterile heparinized venous blood was obtained from 19 patients with CLL, and
one with diffuse well-differentiated lymphocytic lymphoma (DWDL) followed at the North
Shore University Hospital, Manhasset, NY. 17 males and three females, aged 50-86 yr, were
included in this group. Healthy volunteers, sex matched and age approximated, served as
controls. Studies were approved by the Institutional Review Board ofthe North Shore University
Hospital.
Cell Preparation.
￿
PBMC were fractionated into T cell- and non-T cell-enriched subpopu-
lations by rosetting with neuraminidase-treated sheep erythrocytes as described (14). The
nonT cell populations routinely contained <5% CD3+ cells by indirect immunofluorescent
analyses. T cells, obtained from normal volunteers, were exposed to irradiation (1,500 rad)
from a cesium source and were used to provide normal allogeneic helper function (15).
Reagents.
￿
PWM (Gibco Laboratories, Grand Island, NY), PMA (Sigma Chemical Co.,
St. Louis, MO), and Staphylococcus aureus Cowan strain I (SAC ; Calbiochem-Behring Corp.,
La Jolla, CA) were used at 1 :500, 10 ng/ml, and 0.01% final concentrations, respectively,
to induce B cell differentiation.
Culture Conditions.
￿
All cell suspensions were cultured in RPMI 1640 medium (Flow Labora-
tories, McLean, VA) supplemented with penicillin (100 U/ml), streptomycin (100 ug/ml), 2
mM glutamine, and 10% heat-inactivated FCS (all from Gibco Laboratories). Cell cultures
were seeded in 24-well plates (Linbro; Flow Laboratories) at 106 cells/ml in 1 ml vol and in-
cubated at 37°C in a 5% CO2 humidified atmosphere. When indicated, irradiated allogeneic
T cells (3 x 106) and non-T cells (106) were reconstituted at a 3:1 ratio in 2 ml total vol.
Assessment of B Cell Differentiation.
￿
NonT cells were cultured in the presence of medium
alone, or appropriate amounts of PMA, SAC, or irradiated normal allogeneic T cells and
PWM. Cultures were harvested on day 7, and supernatants were frozen at -20°C . The total
amount ofIg in the supernatants was detected by enzyme immunoassay (EIA) as previously
described (16). When indicated, assays were developed with L chain-specific (x or X)
peroxidase-conjugated goat anti-human antibodies to determine heterogeneity of antibody
populations.
Immunofuorescent Analyses.
￿
Surface membrane phenotypes were determined by indirect
immunofluorescence using a battery of murine mAb and flow cytometry as described (17).
In certain cases, non-T cells were sorted into enriched CD5+ populations using a FACS 440
flow cytometer (Becton Dickinson & Co., Mountain View, CA) as described (18).
Assays ofAnti-DNA and Rheumatoid Factor Antibodies.
￿
Levels of ssDNA and dsDNA anti-
bodies in serum and culture supernatants were determined by solid-phase EIA according
to the method ofEaton et al. (19) . To permit the convenient detection of anti-gamma globulin
activity by a similar solid-phase EIA, without requiring isolation of the secreted Ig from cul-
ture supernatants, plates were coated with 10 wg/ml of rabbit gamma globulin (RGG). Thus,
the operational definition of rheumatoid factor (RF) in this study was binding to heterolo-
gous IgG, a technique that detects the majority, but not all, human RFs (20-23).
To allow for comparison of data obtained over the 18-mo period of this prospective study,
an arbitrary binding unit system was devised in which the OD units of the experimental
groups were divided by the OD units, obtained in the same assay, of monoclonal human
autoantibodies reactive with RGG (Q39), ssDNA (W8; reference 18), and dsDNA (W4; ref-
erence 18), and then multiplied by 10 . Values >1.0 were considered significant.
Results
Patient Population.
￿
20 Caucasian patients (17 males and three females, aged 50-86
yr) with documented CD5+ chronic B cell malignancies were studied . 19 patientsSTHOEGER ET AL.
had CLL and one (No. 20) had DWDL. Table I summarizes the clinical features
of these patients with current white blood cell counts, clinical stage according to
the Rai classification (24), and modes of treatment. 50% of the patients showed low
levels of serum gamma globulins and one patient (No. 8) had a prior episode of au-
toimmune hemolytic anemia; none of the others had autoimmune phenomena nor
rheumatic features.
All the B cell malignancies studied were of the CD5-expressing variety. Although
the percentage of CD5+ cells agreed very closely with the numbers of slg+ and Bl+
cells, the density ofCD5 expression varied between different patients (data not shown).
In two cases, s1g was not detected by indirect immunofluorescent analyses despite
repeated surface marker studies, although other B cell markers, such as DR, B1,
and B4, were easily detectable. In one of these patients, IgG x secretion was de-
tected after in vitro culture (No. 19), whereas in the other (No. 3), no Ig synthesis
was ever found. The majority of patients' B cellsexpressed surface IgM; 12 in associ-
ation with x L chains and three with X L chains . Three patients displayed an IgG
surface phenotype; two (Nos. 5 and 10) in association with a, L chains and the other
(No. 13) in association with x L chains.
In Vitro Ig Production by B Lymphocytesfrom Patients with Chronic LymphoidMalignancies.
Peripheral blood non-T cells from these patients were cultured in medium alone or
TABLE I
Clinical and Cellular Characteristics of Patients with CD5' B Cell Leukemias
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* Clinical staging according to Rai classification (24).
l chlr, chlorambucil; ctx, cytoxan; pred, prednisone; vcr, vincristine; dex, dexamethasone; spin irrad, splenic
irradiation.
4 bid, below level of detection.
Patient
No . Age Sex Dx
Duration
of disease
Clinical
stage*
WBC count
(x 10=1)
Surface
Ig
Past/present
therapyl
yr yr
1 65 M CLL 4 III 40 .0 PK chlr; pred
2 65 M CLL 3 0 27 .6 pic None
3 79 M CLL 9 IV 11 .5 bld4 ctx ; vcr; pred
4 65 M CLL 3 0 50.0 4x None
5 67 M CLL 3_ II 7 .9 y ctx ; vcr; dex
6 70 F CLL 9 II 87 .0 Pic None
7 67 M CLL 1 0 32.0 AK None
8 68 M CLL 4 IV 58 .0 AK ctx; vcr; pred
9 50 M CLL 3 IV 18 .9 px chlr; splenectomy
10 68 M CLL 5 11 53.0 y chlr
11 66 M CLL 5 I 84.2 AK None
12 66 M CLL 2 II 170.0 gX chlr; pred
13 54 F CLL 2 II 6.0 yK spin irrad; ctx; vcr
14 64 M CLL 2 IV 29.5 VK ctx; pred; vcr
15 59 M CLL >10 IV 127 .0 pic Fludarabine
16 60 M CLL 8 IV 57.0 px ctx; vcr; pred; chlr;
i .v. gamma globulin
17 86 F CLL >10 0 31 .0 PK None
18 68 M CLL 6 IV 12.5 PLx None
19 70 M CLL 10 II 106.0 bid chlr; vcr; pred
20 59 M DWDL 1 I 10.2 p) None258
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in the presence ofeither PMA, SAC, or irradiated normal T lymphocytes plus PWM.
After 7 d, the supernatants of the individual cultures were collected and assayed
for Ig content by EIA . Table II lists the results of these analyses.
Significant levels ofIg were detected in cultures from 17 of the 20 patients studied;
these levels ranged from 5 to 100 ng/ml. Only three patients (Nos. 1-3) failed to
produce significant amounts of Ig even after mitogenic stimulation. Several patterns
of Ig synthesis were seen in the cultures of the other 17 non-T cell preparations. In
six casés, stimulation by one or several mitogens resulted in the elaboration of
significantly more Ig than found in unstimulated control cultures (Nos. 4-9); in six
other cultures, significant, albeit less impressive, augmentation of Ig synthesis was
found after mitogen stimulation (Nos. 10-15). Of these 12 patients, three were in-
duced to differentiate with PMA (Nos. 11, 13, and 15), four with both PMA and
allogeneic T cells plus PWM (Nos. 4, 6, 8, and 14), one with SAC and PMA (No.
9), three with all combinations (Nos. 5, 7, and 12), and one only by allogeneic T
cells plus PWM stimulation (No. 10). In control cultures, irradiated allogeneic normal
T cells failed to produce significant amounts of Ig. In cultures from patients Nos.
16-20, mitogen stimulation was either ineffective in augmenting Ig synthesis or resulted
in lower levels of Ig production. Thus, heterogeneous patterns of Ig production were
seen among these 20 patients with CLL and DWDL. Nevertheless, the B cell popu-
lations from the majority of patients elaborated sufficient amounts of Ig, under one
or several culture conditions, to allow analysis of autoantibody reactivity.
TABLE II
Differentiation Capacities of CD5 * B Cell Malignancies
Values represent arithmetic means of triplicate or quadruplicate determinations ofOD units
at 490 nm . Background values (never in excess of 0 .005) have been subtracted in each case.
Culture supernatants were measured at 1 :5 dilution.
Patient
No. Disease Medium
Cultures
SAC
stimulated
PMA
with:
Irradiated normal
T cells plus
PWM
1 CLL 0.003 0.008 0.000 0.027
2 CLL 0.000 0.000 0.000 0.000
3 CLL 0.000 0.000 0.000 0.010
4 CLL 0.175 0.180 0 .447 0.416
5 CLL 0.081 0.234 0 .309 0.315
6 CLL 0.290 0.352 0 .699 0.408
7 CLL 0 .044 0.275 1 .286 0.645
8 CLL 0 .563 0.556 1 .292 1 .406
9 CLL 0 .114 0.394 0 .408 ND
10 CLL 0.006 0 .024 0.016 0.164
11 CLL 0.104 0 .111 0.260 0.104
12 CLL 0.179 0 .322 0304 0 .279
13 CLL 0.416 0.496 0.780 ND
14 CLL 0.184 ND 0.572 0 .429
15 CLL 0.292 0.222 0A18 0 .320
16 CLL 0.526 0.470 0.722 0.596
17 CLL 0.802 0.502 0.124 0.498
18 CLL 0.624 0.707 0.326 0.332
19 CLL 0 .379 0.382 0 .397 0.442
20 WDL 0 .808 1 .093 0 .953 0.711STHOEGER ET AL.
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Autoantibody Production by CD5+ CLL and DWDL B Lymphocytes.
￿
Supernatants
from the cultures of the 17 patients that contained significant Ig were assayed by
EIA for reactivity with RGG, ssDNA, or dsDNA. As noted in Table III, Ig from
cultures from nine of the 17 patients tested were found to bind significantly as RFs
or anti-DNA antibodies. Although data foronly one culture are reported in thetable,
it should be noted that everyculture supernatantcontaining Ig was tested andfound
to have similar autoantibody reactivity. Up to 10 wg/ml of control monoclonal Ig
purified from the sera of patients with macroglobulinemia and myeloma (which
represents as much as a 100-fold excess abovethe Ig levels found in the most efficient
leukemic cell cultures) showed no reactivity with RGG, ssDNA, or dsDNA.
Several patterns of Ig reactivity with the three autoantigens tested were seen. In
certain situations, restricted reactivity with only one autoantigen was seen. For in-
stance, the secreted Ig from patients Nos. 7 and 8 appeared to react only with RGG
andthat from patient No. 11 almost exclusively with dsDNA. However, in the majority
of situations, reactivities with multiple antigens were seen. Ig from patient No. 6
reacted with ssDNA and RGG, No. 13 reacted with both ssDNA and dsDNA, Nos.
5 and 15 reacted with dsDNA and RGG, and, finally, Nos. 17 and 20 reacted with
all three antigens tested. Thus, seven of these nine autoantibodies reacted, as rheu-
matoid factors with varying degrees of DNA crossreactivities. The inability to pre-
cisely determine Ig contents in the various supernatants prevents us from making
TABLE III
Reactioities of Igs Produced by CD5 + B Cell Malignancies
with Rabbit IgG, dsDNA, and ssDNA
Data for each antigen represent arbitrary binding units determined by dividing
the OD units obtained for each sample by the OD units obtained using control
human mAb reactive with RGG (Q39), ssDNA (W8), and dsDNA (W4), then
multiplying by 10. Values >1.0 are considered significant. Irrelevant, mono-
clonal human Ig (up to 10 kg/ml) were assayed concomitantly and found to be
negative.
Patient
No.
Mitogen
used
Rabbit
gamma
globulin
Reactivity with:
ssDNA dsDNA
4 T + PWM 0.42 0.00 0 .00
5 T + PWM 1 .21 0.50 2 .34
6 PMA 5.12 6.59 0 .26
7 T + PWM 2.85 0.00 0.09
t3 T + PWM 2.28 0.00 0.00
9 PMA 0.00 0.00 0.00
10 T + PWM 0.67 0.00 0.00
11 PMA 0.33 1 .27 16.61
12 T + PWM 0.42 0.00 0.00
13 PMA 0.08 6.72 3.70
14 PMA 0.00 0.00 0.00
15 T + PWM 1 .41 0.21 2.29
16 PMA 0.00 0.00 0.00
17 T + PWM 50.38 4.87 15.04
18 T + PWM 0.85 0.00 0.00
19 T + PWM 0.00 0.00 0.00
20 PMA 1 .56 1 .23 3.21260
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accurate comparisons ofrelative binding avidity for the various autoantigens in the
instances of multiple antigenic reactivity.
Monotypic Ig L Chains of Secreted Autoantibodies.
￿
To determine if the supernatant
Ig that bound to the autoantigen(s) was indeed the monoclonal product ofthe CD5-
expressing CLL or DWDL cells cultured, the L chain phenotypes of the autoanti-
bodies were determined and compared with that found on the surface of the leu-
kemic cells. The data in Table IV represent the results of companion EIA using
the same supernatants as listed in Table III, developed with either goat anti-human
K or X antibodies. Control human monoclonal Ig of different L chain types at con-
centrations up to 10 N g/ml were reacted with the L chain-specific goat anti-human
antibodies and failed to demonstrate crossreactivity between these antibodies. As
listed in Table IIl, there was a clear indication that the Ig binding to the autoantigen
was monotypic as determined by L chain type. In all but one case, >99% of the
autoantibodies detected by EIA displayed one L chain type. The only exception oc-
curred with patient No. 20, the only case of DWDL studied. In this instance, X anti-
bodies predominated, although K antibodies also were detectable. This result, how-
ever, correlates with the clinical situation since the patient's peripheral blood sample
(white blood count, 10,200) was not a monoclonal B lymphocyte population. Al-
though a lymph node that had been surgically removed for diagnostic purposes con-
tained >65% CD5+/sIgM X+ cells, the peripheral blood nonT cells displayed only
a slight clonal excess of X L chain-bearing nonT cells. The lack of peripheral B cell
monoclonality is consistent with the patient's diagnosis since patients with DWDL
usually have a monoclonal expansion of those B cells residing in the lymph nodes
and less so in the circulating blood. In this and all the other cases, the L chain type
detected on the surface of the overexpanded CD5+ B cell clone agreed exactly with
that detected on the autoantibody.
Similar cultures were established with nonT cells from 10 sex-matched and age-
approximated normal individuals. The total Ig levels of these cultures ranged from
50 to 1,000 ng/ml (data not shown). As noted in Table V, the majority of normal
individuals secreted Ig reactive with RGG, whereas only two showed insignificant
TABLE IV
Ig L Chain Expression of Autoantibodies Produced by CD5+ B Cell Malignancies
Data are represented as the percent reactivity for a given Ig L chain type obtained by dividing
the total OD units (at 490 nm) by the OD units obtained for the individual L chains . Enzyme
immunoassays were performed with the same supernatants as depicted in Table III. However,
one set was developed with affinity-purified goat anti-human Kand the other with goat antihu-
man X antibodies to allow definition of L chain phenotypes of autoantibodies.
Patient
No . sIg
RGG
K Á
ssDNA
K í~ .
dsDNA
K Á
5 y <1 .0 >99.0 <1 .0 >99.0 ND ND
6 pK >99.0 <1 .0 >99.0 <1 .0 ND ND
7 pK >99.0 <1 .0 ND ND ND ND
8 uK >99.0 <1 .0 ND ND ND ND
11 wK ND ND >99.0 <1 .0 >99.0 <1 .0
13 yK ND ND >99.0 <1 .0 >99.0 <1 .0
15 4K >99.0 <1 .0 ND ND ND ND
17 wK >99.0 <1 .0 >99.0 <1 .0 >99.0 <1 .0
20 gX 33.0 67.0 14.0 86.0 31 .0 69 .0Binding units determined as per Table 111.
reactivity with ssDNA or with dsDNA. Unlike the situation with the patients with
the lymphoproliferative disorders, all ofthese autoantibodies were polyclonal exhibiting
both L chain types (data not shown) .
Production ofAutoantibodies by Pure Populations of CD5+ B Cells.
￿
To confirm that the
autoantibodies were the products ofthe CD5-expressing clone and not contaminating
CD5- cells, nonT cells from patient No. 11 (which had been shown to secrete anti-
DNA antibodies; Tables III and IV) were purified further by a FACS using an mAb
reactive with CD5 and FITC-conjugated goat anti-mouse antibodies.
As shown in Fig. 1, before sorting, 98% of the nonT cells expressed CD5 (A);
only a very small CD5- population existed, falling between channels 1 and 8. In
addition, only 1.7 % of the presorted cellsexpressed CD3 (Fig. 1 B), these cellsfalling
W m
z
W
V
TABLE V
Reactivities with RGG, ssDNA, and dsDNA of Polyclonal Igs Secreted
by PWM-stimulated B Lymphocytes from Normal Individuals
STHOEGER ET AL.
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FIGURE 1 .
￿
CD5 expression of leukemic non-T cells before and after cell sorting. Dotted lines
represent results obtained with a control sample stained with an irrelevant mAb of the same
isotype as the anti-CD5 mAb. Solid lines represent data obtained with the anti-CD5 mAb. (A)
Histogram of indirect immunofluorescent staining of fresh, unsorted non-T cells from patient
No. 11 with anti-CD5 rnAb; percent C135-reactive cells, 98%. Arrows illustrate the gates used
for subsequent cell sorting. (B) Staining of unsorted non-T cells with anti-CD3 mAb; percent
CD3-reactive cells, 1.7%. (C) Reanalysis of Blymphocytes for CD5 expression post sorting; per-
cent CD5-reactive cells, 99.8%.
Normal
donor Age
yr
Sex RGG
Reactivity with:
ssDNA dsDNA
1 39 M 1 .95 0 .00 0.00
2 61 F 0.45 0 .00 0.00
3 53 F 0.60 0 .00 0.00
4 59 M 2.82 0.00 0.00
5 69 M 1 .94 0 .00 0.00
6 53 F 2 .36 0.00 0.00
7 65 M 4 .39 0.65 0.00
8 57 M 4.86 0.00 0.53
9 58 M 0.01 0.00 0.00
10 58 M 1 .21 0.00 0 .00262
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between channels 0 and 67 . Sorting conditions were such that only those cells
registering above channel 67 were collected, which represented the more intensely
stained CD5-expressing B cells and excluded the CD5 - cells and T cells. After
sorting and before culturing, the isolated population was reanalyzed for CD5 ex-
pression . As shown in Fig. 1 C, 99.8% o£ the sorted cells expressed surface CD5
antigen.
These highly enriched C135-expressing cellswere cultured in the presence of PMA,
the optimal differentiating agent in the initial set of experiments (Table II). Super-
natants collected from this culture demonstrated that the sorted cells were induced
to differentiate by PMA stimulation, although the levels of secreted Ig were less than
those ofthe unsorted cells. Nevertheless, the supernatants from these cells contained
anti-dsDNA antibodies (4.1 U as defined by the binding assay described in Table
III) that displayed only x L chains.
To rule out the possibility that the inability to detect autoantibody production
in certain cultures was due to the presence of an insufficient number of CD5+ cells,
non-T cells from patient No. 12 were similarly sorted and stimulated in vitro to elaborate
Ig. Neither the presorted nor sorted C135-expressing B cell populations from this
patient produced significant amounts of Ig reactive with either RGG, ssDNA, or
dsDNA. Thus, it is clear that certain, but not all, clones of B cells expressing the
CD5 antigen synthesize autoantibodies reactive with Ig or DNA.
Analyses ofSerumfor Autoantibodiesfrom CLL/DWDL Patients.
￿
Serum from the CLL
patients studied above and from normal controls were analyzed by EIA for reac-
tivity with RGG, ssDNA, and dsDNA. In these sensitive enzyme immunoassays,
all ofthe sera tested contained low and variable amounts of autoantibodies that were
well below the levels seen in sera from patients with rheumatoid arthritis and SLE
used as controls in the same assays (data not shown).
Discussion
The experiments presented in this studymade use oftwo important features relating
to the leukemic cells of CLL and related B cell lymphoproliferative disorders. First,
the leukemic cells represent monoclonal expansions of CD5-expressing B lympho-
cytes (8-12) and second, they can be made to secrete antibody in vitro when stimu-
lated with a battery ofT cell-dependent and T cell-independent mitogens (reviewed
in references 25 and 26) . Thus, after 7 d in vitro, 17 of the 20 samples studied were
found to elaborate significant amountE of Ig (Table II). Of these 17 Ig-producing
B cell samples, 12 produced more Ig after stimulation with one or several of the
T cell-independent mitogens PMA or SAC, and/or a T cell-dependent mitogen
(PWM) in the presence of irradiated allogeneic T cells from normal individuals.
These data are in agreement with prior studies demonstrating that CLL B lympho-
cytes can be made to differentiate to antibody-secreting cells when appropriately
stimulated in vitro. This was initially demonstrated by Fu et al. (27) in selected CLL
patients with serum monoclonal gammopathies. With the aid of heterologous anti-
idiotypic antibodies, these investigators showed that the CLL leukemic cells could
be differentiated to plasma cells by providing normal T helper function. Subsequently,
Robert et al. (28) showed that by using a battery of T cell-dependent and T cell-in-
dependent mitogens, B cells from the majority of CLL patients could be induced
to secrete antibodies with monotypic L chains identical to those displayed on the
leukemic cell surface.STHOEGER ET AL.
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The antibodies produced by the Ig-secreting cells in this study were assayed by
EIA for reactivity with ssDNA, dsDNA, and IgG. A surprisingly high number of
patients (>50%; 9:17) were found to synthesize Ig reactive with one or several of
these autoantigens. As shown in Table III, antibodies from five patients were reac-
tive with ssDNA, six with dsDNA, and seven with RGG (RFs). RGG was used as
the target in the RF immunoassays since it allowed the determination of IgG reac-
tivity without requiring isolation and labeling of the RF from the culture superna-
tants. It should be mentioned that although certain human RFsreact only with human
IgG or with only rabbit IgG, most react with both (20-23). The possibility that in
certain instances autoantibodies were not detected by our assays because the leu-
kemic cells did not produce sufficient amounts of Ig also cannot be ruled out. In-
deed, cultures from patients Nos. 4, 10, 12, and 18 demonstrated low levels of RF
activity that were not considered significant in our arbitrary binding unit system.
Experiments are currently underway to create hybridomas with CD5' cells from
selected patients that will allow collection of larger quantities of Ig to test these hy-
potheses. Furthermore, additional autoreactive clones might be detected amongthese
patients if a more comprehensive autoantigen panel is used. This is also presently
being tested.
The autoantibodies secreted by thepatients' B cells displayed monotypic Ig Lchains
that were identical to that expressed on the surface of the CD5' leukemic cells
(Table IV), strongly suggesting that they were the products of the CD5-expressing
clone. Nevertheless, to rule out the unlikely possibility that contamination with
CD5- B cells was responsible for the autoantibody production observed, the non-T
cell fraction from patient No. 11 was purified further by a FAGS into >99.8% CD5*
B cells. Supernatants from mitogen-stimulated cultures ofthese cells reactedstrongly
with dsDNA, demonstrating the production of autoantibodies by this CD5' B cell
clone. Thus, the autoantibodies detected in these cultures were the clonal products
of the CD5-expressing B cells.
As expected, similarcultures ofnonT cells from normal volunteers produced higher
levels of Ig compared with the CLL cultures. Most of these supernatants exhibited
RF activity with minimalssDNA or dsDNAreactivity (Table V), afinding in agree-
ment with studies described by other investigators (29, 30). These RFs were poly-
clonal antibodies since they exhibited both x and X L chain usage. However, despite
the relatively high levels ofIg in the supernatants, the RF activity in severalinstances
waslower than that seen for theCLL samples. This most likely reflects the fact that
only a minority of the normal peripheral blood nonT cells are CD5' whereas the
majority are CD5- (31, 32). Therefore, most of the Ig secreted by the normal cells
probably is derived from the CD5- population and is reactive with conventional
antigens, while a smaller amount comes from the CD5' cells and reacts with au-
toantigens. A more relevant set of control cells for our study would be monoclonal
populations of CD5- B cells. We have been able to study only a limited number
of patients with CD5- B cell malignancies to date (four patients with hairy cell
leukemia). Although the number ofpatients evaluated is too small to draw firm con-
clusions, so far, Ig from cultures of these cells have not shown autoreactivity.
Thedata in the present study areconsistent with experiments performed in mice
demonstrating that Ly-1 + B lymphocytes preferentially produce antibodies reactive
with autologous erythrocytes, thymocytes, IgG, or ssDNA (3, 6, 7). Studies in man
have shown that higher than normal numbers (31-37) of CD5-expressing cells can264
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be found in selected patients with autoimmune disorders (38, 39). In addition, our
data support and extend the observations of Casali et al. (31) and Hardy et al. (32)
showing that enriched polyclonal populations of CD5+ B cells, taken from normal
peripheral or umbilical cord blood, secrete autoantibodies after EBV infection or
SAC stimulation. However, several features and findings make the studies reported
here distinct from those just mentioned .
First, only in the present study have monoclonal populations of human CD5+
B cells been used to demonstrate autoantibody production, definitively illustrating
that the autoantibodies are products of the C135-expressing B cells. Second, the
specificities of the autoantibodies detected deserve special comment . Six patients'
B cells secreted mAbs reactive with dsDNA (Table III), a set of autoantibodies that
usually correlates best with autoimmune symptomatology and that has been con-
sidered relatively specific for SLE (40). To date, dsDNA production by polyclonal
populations of CD5+ or Ly-l' B cells has not been reported.
Certain of these dsDNA-reactive autoantibodies also behaved as RFs (patients Nos.
5, 15, 17, and 20). One of these dsDNA/RF mAbs appears to bind IgG better than
dsDNA (No. 17). This autoantibody may be a monoclonal representation of the subset
of mAb shown to bind IgG and DNA-histone complexes, an RF group that displays
a unique crossreactive idiotype (41). Since the other three dsDNA/RF mAbs (Nos.
5, 15, and 20) appear to bind dsDNA more effectively, they probably do not fall
into this group. In addition, it is noteworthy that certain of the RFs secreted by
our patients contained X L chains (Nos. 5 and 20), an L chain type infrequently
associated with RFs clinically but overutilized by Ly-1+ B cells in the mouse (7).
Our demonstration that certain patients with CLL secrete RF provides confirma-
tory evidence for the studies of Preud'Homme and Seligmann (42), showing that
the expanded B cell clone of selected patients with lymphoproliferative disorders can
bind IgG to surface membrane-bound IgM molecules.
Finally, previous studies in mouse (3, 5-7) and man (32, 33, 35, 36) have sug-
gested that most, if not all, of the autoreactive Ly-1/CD5+ clones display an
IgM + /IgD' surface phenotype. In addition, the autoreactive antibodies generated
by CD5+ human B cells are usually of the IgM isotype (32, 43) . In the present
study, CD5+ cells from four patients (Nos. 5, 10, 13, 19) synthesized IgG and two
of these four produced autoantibodies reacting with either dsDNA and IgG (No.
5) or ssDNA and dsDNA (No. 13). Thus, these patients illustrate that CD5 + /IgG+
cells exist in man and certain clones with this phenotype can produce IgG autoanti-
bodies.
Although the autoantibodies produced by the CD5' B cells in this study are
monoclonal, the majority of these mAb are "polyspecific;' binding to a number of
different autoantigens (Table III). Such polyspecific autoantibodies have been de-
scribed previously in human (44) and murine (45) sera, as well as among human
monoclonal autoantibodies (43, 46).
The preceding data may help to understand certain clinical observations about
patients with CLL. Since our data demonstrate that B cells from a remarkably high
percentage (>50%) of patients with C135-expressing lymphoproliferative disorders
synthesize autoreactive antibodies, this may relate to the findings that the sera of
some patients display autoantibodies or that certain patients develop frank autoim-
mune problems, such as autoimmune hemolytic anemia (13). However, consideringSTHOEGER ET AL .
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that all patients with CLL develop an overexpansion of the CD5-expressing B cell
lineage, it is surprising that many more patients do not experience autoimmune com-
plications or have high levels of autoantibodies in their sera . The absence of these
phenomena may be a reflection ofeither a lack ofcorrelation between these phenomena
and the expanded CD5+ clone and/or a specific differentiation block whereby only
a few cells ofthe malignant clone undergo terminal maturation to antibody-secreting
cells . This failure to terminally differentiate may be due, in part, to aTh defect (47) .
Finally, the presented data are consistent with the notion that the autoreactivity
of CD5+ B cells may play a role in the clonal expansion seen in these lym-
phoproliferative disorders . Repetitive crosslinking ofsurface Ig receptors by autoan-
tigens may lead to proliferation and expansion of the CD5+ clone. Because of the
differentiation block mentioned above, this clone may not mature to plasma cells
that could induce negative feedback signals . The high incidence ofB cell malignan-
cies in mice (48) and in humans (49, 50) with autoimmune diseases may in part
be a reflection of this or a related mechanism.
Summary
CD5-expressingB lymphocytes from patients with selected chronic lymphoprolifer-
ative disorders were used to determine whether monoclonal populations of CD5+
human B cells produce autoantibodies . CD5+ B cells from 19 patients with chronic
lymphocytic leukemia (CLL) and one with diffuse well-differentiated lymphocytic
lymphoma (DWDL) were cultured, with and without mitogenic stimulation, to ob-
tain Ig from these cells . 17 of the 20 samples produced Ig in vitro. mAb from nine
of the 17 patients were reactive with either IgG, ssDNA, or dsDNA . In every in-
stance, the autoantibodies displayed monotypic L chain usage that correlated pre-
cisely with the L chain expressed on the CD5+ leukemic B cell surface. These mono-
clonal autoantibodies varied in their degree ofantigenic specificity ; some were quite
specific, reacting with only one antigen, whereas others were polyspecific, reacting
with two or all three autoantigens tested .
Three features distinguish these autoantibodies from those observed in prior studies
ofCD5+ B cells . First, they are clearly the products of monoclonal populations of
CD5' cells ; second, several react with dsDNA, a specificity not previously reported
and often seen in association with significant autoimmune disorders ; and third, two
of the monoclonal autoantibodies secreted by the CD5' clones were of the IgG class .
Although not all of the Ig-producing, C135-expressing clones elaborated mAbs reac-
tive with the autoantigens tested, >50% did . It is possible that with a broader au-
toantigenic panel or with larger quantities ofCLL/DWDL-derived Ig, even more
autoantibody-producing clones might be identified . These studies may have impor-
tant implications for the antigenic specificity of subsets of human B lymphocytes
as well as for lymphoproliferative and autoimmune disorders in general .
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